Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
BCAL Diagnostics Limited on 6ix
Earlier from BCAL Diagnostics
- GSS: Response to Media Speculation & BCAL letter to GSS
- BREASTESTplus 2 clinically validated
- BCAL Introduces Avantect Multi-Cancer Early Detection Test
- Appendix 4E and Annual Report to shareholders
- BCAL Takes Interest in Genetic Signatures to 18.46%
Follow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics